ShockWave Medical, Inc.
ShockWave Medical, Inc. SWAV Peers
See (SWAV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SWAV | $334.75 | -0.02% | 12.57B | 78.76 | $4.25 | N/A |
| ABT | $134.78 | +1.07% | 234.50B | 17.53 | $7.69 | +1.69% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $106.04 | +1.12% | 156.87B | 77.40 | $1.37 | N/A |
| SYK | $394.29 | +0.53% | 150.68B | 53.21 | $7.41 | +0.83% |
| MDT | $86.42 | +0.36% | 110.84B | 26.35 | $3.28 | +3.25% |
| EW | $78.00 | +1.46% | 45.75B | 32.23 | $2.42 | N/A |
| DXCM | $85.48 | -0.22% | 33.52B | 64.27 | $1.33 | N/A |
| STE | $251.44 | +1.85% | 24.70B | 40.75 | $6.17 | +0.89% |
| PODD | $324.75 | +0.85% | 22.85B | 56.28 | $5.77 | N/A |
Stock Comparison
SWAV vs ABT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ABT has a market cap of 234.50B. Regarding current trading prices, SWAV is priced at $334.75, while ABT trades at $134.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ABT's P/E ratio is 17.53. In terms of profitability, SWAV's ROE is +0.25%, compared to ABT's ROE of +0.24%. Regarding short-term risk, SWAV is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BSX-PA Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, SWAV is priced at $334.75, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SWAV's ROE is +0.25%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, SWAV is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BSX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BSX has a market cap of 156.87B. Regarding current trading prices, SWAV is priced at $334.75, while BSX trades at $106.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BSX's P/E ratio is 77.40. In terms of profitability, SWAV's ROE is +0.25%, compared to BSX's ROE of +0.10%. Regarding short-term risk, SWAV is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SYK Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SYK has a market cap of 150.68B. Regarding current trading prices, SWAV is priced at $334.75, while SYK trades at $394.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SYK's P/E ratio is 53.21. In terms of profitability, SWAV's ROE is +0.25%, compared to SYK's ROE of +0.11%. Regarding short-term risk, SWAV is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs MDT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, MDT has a market cap of 110.84B. Regarding current trading prices, SWAV is priced at $334.75, while MDT trades at $86.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas MDT's P/E ratio is 26.35. In terms of profitability, SWAV's ROE is +0.25%, compared to MDT's ROE of +0.09%. Regarding short-term risk, SWAV is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs EW Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, EW has a market cap of 45.75B. Regarding current trading prices, SWAV is priced at $334.75, while EW trades at $78.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas EW's P/E ratio is 32.23. In terms of profitability, SWAV's ROE is +0.25%, compared to EW's ROE of +0.49%. Regarding short-term risk, SWAV is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs DXCM Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, DXCM has a market cap of 33.52B. Regarding current trading prices, SWAV is priced at $334.75, while DXCM trades at $85.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas DXCM's P/E ratio is 64.27. In terms of profitability, SWAV's ROE is +0.25%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, SWAV is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs STE Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, STE has a market cap of 24.70B. Regarding current trading prices, SWAV is priced at $334.75, while STE trades at $251.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas STE's P/E ratio is 40.75. In terms of profitability, SWAV's ROE is +0.25%, compared to STE's ROE of +0.09%. Regarding short-term risk, SWAV is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs PODD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PODD has a market cap of 22.85B. Regarding current trading prices, SWAV is priced at $334.75, while PODD trades at $324.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PODD's P/E ratio is 56.28. In terms of profitability, SWAV's ROE is +0.25%, compared to PODD's ROE of +0.35%. Regarding short-term risk, SWAV is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs PHG Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PHG has a market cap of 22.24B. Regarding current trading prices, SWAV is priced at $334.75, while PHG trades at $24.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PHG's P/E ratio is 82.90. In terms of profitability, SWAV's ROE is +0.25%, compared to PHG's ROE of +0.03%. Regarding short-term risk, SWAV is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ZBH Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ZBH has a market cap of 19.18B. Regarding current trading prices, SWAV is priced at $334.75, while ZBH trades at $96.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ZBH's P/E ratio is 21.54. In terms of profitability, SWAV's ROE is +0.25%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SWAV is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ABMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, SWAV is priced at $334.75, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SWAV's ROE is +0.25%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SWAV is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ALGN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ALGN has a market cap of 13.65B. Regarding current trading prices, SWAV is priced at $334.75, while ALGN trades at $188.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ALGN's P/E ratio is 34.17. In terms of profitability, SWAV's ROE is +0.25%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, SWAV is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SNN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SNN has a market cap of 12.63B. Regarding current trading prices, SWAV is priced at $334.75, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SNN's P/E ratio is 30.71. In terms of profitability, SWAV's ROE is +0.25%, compared to SNN's ROE of +0.08%. Regarding short-term risk, SWAV is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs PEN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PEN has a market cap of 10.87B. Regarding current trading prices, SWAV is priced at $334.75, while PEN trades at $280.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PEN's P/E ratio is 262.29. In terms of profitability, SWAV's ROE is +0.25%, compared to PEN's ROE of +0.04%. Regarding short-term risk, SWAV is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs GMED Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, GMED has a market cap of 8.29B. Regarding current trading prices, SWAV is priced at $334.75, while GMED trades at $61.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas GMED's P/E ratio is 45.70. In terms of profitability, SWAV's ROE is +0.25%, compared to GMED's ROE of +0.05%. Regarding short-term risk, SWAV is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BIO Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BIO has a market cap of 6.78B. Regarding current trading prices, SWAV is priced at $334.75, while BIO trades at $248.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BIO's P/E ratio is -3.80. In terms of profitability, SWAV's ROE is +0.25%, compared to BIO's ROE of -0.32%. Regarding short-term risk, SWAV is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BIO-B Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BIO-B has a market cap of 6.72B. Regarding current trading prices, SWAV is priced at $334.75, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BIO-B's P/E ratio is -3.83. In terms of profitability, SWAV's ROE is +0.25%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, SWAV is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for SWAV.
SWAV vs BRKR Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BRKR has a market cap of 5.69B. Regarding current trading prices, SWAV is priced at $334.75, while BRKR trades at $37.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BRKR's P/E ratio is 72.17. In terms of profitability, SWAV's ROE is +0.25%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, SWAV is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs GKOS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, GKOS has a market cap of 5.46B. Regarding current trading prices, SWAV is priced at $334.75, while GKOS trades at $95.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas GKOS's P/E ratio is -42.06. In terms of profitability, SWAV's ROE is +0.25%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, SWAV is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NARI Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, SWAV is priced at $334.75, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NARI's P/E ratio is -59.24. In terms of profitability, SWAV's ROE is +0.25%, compared to NARI's ROE of -0.18%. Regarding short-term risk, SWAV is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for SWAV.
SWAV vs INSP Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, INSP has a market cap of 4.51B. Regarding current trading prices, SWAV is priced at $334.75, while INSP trades at $152.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas INSP's P/E ratio is 72.40. In terms of profitability, SWAV's ROE is +0.25%, compared to INSP's ROE of +0.10%. Regarding short-term risk, SWAV is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs IRTC Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, IRTC has a market cap of 4.50B. Regarding current trading prices, SWAV is priced at $334.75, while IRTC trades at $141.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas IRTC's P/E ratio is -45.05. In terms of profitability, SWAV's ROE is +0.25%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, SWAV is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ITGR Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ITGR has a market cap of 4.22B. Regarding current trading prices, SWAV is priced at $334.75, while ITGR trades at $120.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ITGR's P/E ratio is 56.25. In terms of profitability, SWAV's ROE is +0.25%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, SWAV is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs TMDX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, TMDX has a market cap of 4.11B. Regarding current trading prices, SWAV is priced at $334.75, while TMDX trades at $121.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas TMDX's P/E ratio is 85.02. In terms of profitability, SWAV's ROE is +0.25%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, SWAV is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs AXNX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, SWAV is priced at $334.75, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SWAV's ROE is +0.25%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SWAV is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for SWAV.
SWAV vs PRCT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PRCT has a market cap of 3.21B. Regarding current trading prices, SWAV is priced at $334.75, while PRCT trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PRCT's P/E ratio is -34.36. In terms of profitability, SWAV's ROE is +0.25%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, SWAV is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs LIVN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, LIVN has a market cap of 2.42B. Regarding current trading prices, SWAV is priced at $334.75, while LIVN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas LIVN's P/E ratio is -10.91. In terms of profitability, SWAV's ROE is +0.25%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, SWAV is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NUVA Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, SWAV is priced at $334.75, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SWAV's ROE is +0.25%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SWAV is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs UFPT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, UFPT has a market cap of 1.95B. Regarding current trading prices, SWAV is priced at $334.75, while UFPT trades at $253.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas UFPT's P/E ratio is 31.12. In terms of profitability, SWAV's ROE is +0.25%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, SWAV is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ATEC Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ATEC has a market cap of 1.89B. Regarding current trading prices, SWAV is priced at $334.75, while ATEC trades at $12.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ATEC's P/E ratio is -11.37. In terms of profitability, SWAV's ROE is +0.25%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, SWAV is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CNMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CNMD has a market cap of 1.87B. Regarding current trading prices, SWAV is priced at $334.75, while CNMD trades at $60.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CNMD's P/E ratio is 15.82. In terms of profitability, SWAV's ROE is +0.25%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, SWAV is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs TNDM Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, TNDM has a market cap of 1.54B. Regarding current trading prices, SWAV is priced at $334.75, while TNDM trades at $23.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas TNDM's P/E ratio is -8.27. In terms of profitability, SWAV's ROE is +0.25%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, SWAV is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs HSKA Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, SWAV is priced at $334.75, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SWAV's ROE is +0.25%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SWAV is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for SWAV.
SWAV vs AORT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AORT has a market cap of 1.26B. Regarding current trading prices, SWAV is priced at $334.75, while AORT trades at $29.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AORT's P/E ratio is -57.86. In terms of profitability, SWAV's ROE is +0.25%, compared to AORT's ROE of -0.07%. Regarding short-term risk, SWAV is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs AHCO Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AHCO has a market cap of 1.22B. Regarding current trading prices, SWAV is priced at $334.75, while AHCO trades at $9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AHCO's P/E ratio is 15.55. In terms of profitability, SWAV's ROE is +0.25%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, SWAV is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SILK Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, SWAV is priced at $334.75, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SILK's P/E ratio is -18.96. In terms of profitability, SWAV's ROE is +0.25%, compared to SILK's ROE of -0.37%. Regarding short-term risk, SWAV and SILK have similar daily volatility (0.04).
SWAV vs FNA Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, SWAV is priced at $334.75, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas FNA's P/E ratio is -19.83. In terms of profitability, SWAV's ROE is +0.25%, compared to FNA's ROE of -0.36%. Regarding short-term risk, SWAV is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs IART Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, IART has a market cap of 1.05B. Regarding current trading prices, SWAV is priced at $334.75, while IART trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas IART's P/E ratio is -35.71. In terms of profitability, SWAV's ROE is +0.25%, compared to IART's ROE of -0.03%. Regarding short-term risk, SWAV is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ESTA Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ESTA has a market cap of 1.05B. Regarding current trading prices, SWAV is priced at $334.75, while ESTA trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ESTA's P/E ratio is -12.05. In terms of profitability, SWAV's ROE is +0.25%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, SWAV is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs INMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, INMD has a market cap of 1.02B. Regarding current trading prices, SWAV is priced at $334.75, while INMD trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas INMD's P/E ratio is 6.52. In terms of profitability, SWAV's ROE is +0.25%, compared to INMD's ROE of +0.25%. Regarding short-term risk, SWAV is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CSII Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, SWAV is priced at $334.75, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CSII's P/E ratio is -20.83. In terms of profitability, SWAV's ROE is +0.25%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SWAV is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CRY Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, SWAV is priced at $334.75, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CRY's P/E ratio is 425.71. In terms of profitability, SWAV's ROE is +0.25%, compared to CRY's ROE of -0.07%. Regarding short-term risk, SWAV is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SIBN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, SWAV is priced at $334.75, while SIBN trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SIBN's P/E ratio is -22.60. In terms of profitability, SWAV's ROE is +0.25%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, SWAV is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs IRMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, IRMD has a market cap of 685.47M. Regarding current trading prices, SWAV is priced at $334.75, while IRMD trades at $53.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas IRMD's P/E ratio is 34.78. In terms of profitability, SWAV's ROE is +0.25%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, SWAV is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CBLL Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CBLL has a market cap of 649.49M. Regarding current trading prices, SWAV is priced at $334.75, while CBLL trades at $17.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CBLL's P/E ratio is -14.38. In terms of profitability, SWAV's ROE is +0.25%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, SWAV is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs AVNS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AVNS has a market cap of 606.72M. Regarding current trading prices, SWAV is priced at $334.75, while AVNS trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AVNS's P/E ratio is -1.56. In terms of profitability, SWAV's ROE is +0.25%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, SWAV is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BFLY Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BFLY has a market cap of 583.20M. Regarding current trading prices, SWAV is priced at $334.75, while BFLY trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BFLY's P/E ratio is -7.87. In terms of profitability, SWAV's ROE is +0.25%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, SWAV is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs APEN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, SWAV is priced at $334.75, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas APEN's P/E ratio is -9.43. In terms of profitability, SWAV's ROE is +0.25%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SWAV is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs RXST Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, RXST has a market cap of 576.64M. Regarding current trading prices, SWAV is priced at $334.75, while RXST trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas RXST's P/E ratio is -21.50. In terms of profitability, SWAV's ROE is +0.25%, compared to RXST's ROE of -0.10%. Regarding short-term risk, SWAV is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BFLY-WT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BFLY-WT has a market cap of 575.60M. Regarding current trading prices, SWAV is priced at $334.75, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, SWAV's ROE is +0.25%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, SWAV is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NPCE Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NPCE has a market cap of 573.65M. Regarding current trading prices, SWAV is priced at $334.75, while NPCE trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NPCE's P/E ratio is -18.81. In terms of profitability, SWAV's ROE is +0.25%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, SWAV is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs KIDS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, KIDS has a market cap of 571.42M. Regarding current trading prices, SWAV is priced at $334.75, while KIDS trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas KIDS's P/E ratio is -13.11. In terms of profitability, SWAV's ROE is +0.25%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, SWAV is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs AXGN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AXGN has a market cap of 538.79M. Regarding current trading prices, SWAV is priced at $334.75, while AXGN trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AXGN's P/E ratio is -51.43. In terms of profitability, SWAV's ROE is +0.25%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, SWAV is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs OFIX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, OFIX has a market cap of 475.65M. Regarding current trading prices, SWAV is priced at $334.75, while OFIX trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas OFIX's P/E ratio is -3.28. In terms of profitability, SWAV's ROE is +0.25%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, SWAV is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BVS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BVS has a market cap of 450.57M. Regarding current trading prices, SWAV is priced at $334.75, while BVS trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BVS's P/E ratio is -14.15. In terms of profitability, SWAV's ROE is +0.25%, compared to BVS's ROE of -0.21%. Regarding short-term risk, SWAV is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs TMCI Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, TMCI has a market cap of 422.72M. Regarding current trading prices, SWAV is priced at $334.75, while TMCI trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas TMCI's P/E ratio is -7.91. In terms of profitability, SWAV's ROE is +0.25%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, SWAV is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SRDX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SRDX has a market cap of 408.67M. Regarding current trading prices, SWAV is priced at $334.75, while SRDX trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SRDX's P/E ratio is -28.02. In terms of profitability, SWAV's ROE is +0.25%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, SWAV is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CLPT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CLPT has a market cap of 372.53M. Regarding current trading prices, SWAV is priced at $334.75, while CLPT trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CLPT's P/E ratio is -18.05. In terms of profitability, SWAV's ROE is +0.25%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, SWAV is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NNOX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NNOX has a market cap of 357.07M. Regarding current trading prices, SWAV is priced at $334.75, while NNOX trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NNOX's P/E ratio is -6.15. In terms of profitability, SWAV's ROE is +0.25%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, SWAV is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs OM Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, OM has a market cap of 345.59M. Regarding current trading prices, SWAV is priced at $334.75, while OM trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas OM's P/E ratio is -0.68. In terms of profitability, SWAV's ROE is +0.25%, compared to OM's ROE of -1.45%. Regarding short-term risk, SWAV is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SENS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SENS has a market cap of 338.99M. Regarding current trading prices, SWAV is priced at $334.75, while SENS trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SENS's P/E ratio is -4.71. In terms of profitability, SWAV's ROE is +0.25%, compared to SENS's ROE of -7.46%. Regarding short-term risk, SWAV is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CTKB Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CTKB has a market cap of 338.18M. Regarding current trading prices, SWAV is priced at $334.75, while CTKB trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CTKB's P/E ratio is -29.67. In terms of profitability, SWAV's ROE is +0.25%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, SWAV is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs VREX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, VREX has a market cap of 327.02M. Regarding current trading prices, SWAV is priced at $334.75, while VREX trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas VREX's P/E ratio is -7.65. In terms of profitability, SWAV's ROE is +0.25%, compared to VREX's ROE of -0.08%. Regarding short-term risk, SWAV is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SMLR Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SMLR has a market cap of 312.27M. Regarding current trading prices, SWAV is priced at $334.75, while SMLR trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SMLR's P/E ratio is 6.34. In terms of profitability, SWAV's ROE is +0.25%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, SWAV is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs PACB Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PACB has a market cap of 310.59M. Regarding current trading prices, SWAV is priced at $334.75, while PACB trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PACB's P/E ratio is -0.38. In terms of profitability, SWAV's ROE is +0.25%, compared to PACB's ROE of -1.25%. Regarding short-term risk, SWAV is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs VMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, VMD has a market cap of 267.18M. Regarding current trading prices, SWAV is priced at $334.75, while VMD trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas VMD's P/E ratio is 22.53. In terms of profitability, SWAV's ROE is +0.25%, compared to VMD's ROE of +0.10%. Regarding short-term risk, SWAV is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CERS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CERS has a market cap of 254.24M. Regarding current trading prices, SWAV is priced at $334.75, while CERS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CERS's P/E ratio is -13.30. In terms of profitability, SWAV's ROE is +0.25%, compared to CERS's ROE of -0.35%. Regarding short-term risk, SWAV is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ZIMV Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ZIMV has a market cap of 251.57M. Regarding current trading prices, SWAV is priced at $334.75, while ZIMV trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ZIMV's P/E ratio is -7.33. In terms of profitability, SWAV's ROE is +0.25%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, SWAV is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs MXCT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, MXCT has a market cap of 244.53M. Regarding current trading prices, SWAV is priced at $334.75, while MXCT trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas MXCT's P/E ratio is -5.75. In terms of profitability, SWAV's ROE is +0.25%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, SWAV is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs TCMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, TCMD has a market cap of 241.78M. Regarding current trading prices, SWAV is priced at $334.75, while TCMD trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas TCMD's P/E ratio is 15.76. In terms of profitability, SWAV's ROE is +0.25%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, SWAV is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NVRO Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, SWAV is priced at $334.75, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SWAV's ROE is +0.25%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SWAV is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs EYES Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, SWAV is priced at $334.75, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas EYES's P/E ratio is N/A. In terms of profitability, SWAV's ROE is +0.25%, compared to EYES's ROE of -0.26%. Regarding short-term risk, SWAV is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CATX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CATX has a market cap of 197.82M. Regarding current trading prices, SWAV is priced at $334.75, while CATX trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CATX's P/E ratio is -1.95. In terms of profitability, SWAV's ROE is +0.25%, compared to CATX's ROE of -0.27%. Regarding short-term risk, SWAV is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BWAY Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BWAY has a market cap of 190.61M. Regarding current trading prices, SWAV is priced at $334.75, while BWAY trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BWAY's P/E ratio is 56.11. In terms of profitability, SWAV's ROE is +0.25%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, SWAV is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs QTRX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, QTRX has a market cap of 185.99M. Regarding current trading prices, SWAV is priced at $334.75, while QTRX trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas QTRX's P/E ratio is -3.86. In terms of profitability, SWAV's ROE is +0.25%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, SWAV is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs SGHT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, SGHT has a market cap of 183.54M. Regarding current trading prices, SWAV is priced at $334.75, while SGHT trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas SGHT's P/E ratio is -3.62. In terms of profitability, SWAV's ROE is +0.25%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, SWAV is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ELMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ELMD has a market cap of 180.68M. Regarding current trading prices, SWAV is priced at $334.75, while ELMD trades at $21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ELMD's P/E ratio is 28.73. In terms of profitability, SWAV's ROE is +0.25%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, SWAV is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs BDMD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, BDMD has a market cap of 180.44M. Regarding current trading prices, SWAV is priced at $334.75, while BDMD trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas BDMD's P/E ratio is 14.54. In terms of profitability, SWAV's ROE is +0.25%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, SWAV is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ANIK Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ANIK has a market cap of 174.82M. Regarding current trading prices, SWAV is priced at $334.75, while ANIK trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ANIK's P/E ratio is -16.25. In terms of profitability, SWAV's ROE is +0.25%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, SWAV is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs RCEL Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, RCEL has a market cap of 170.77M. Regarding current trading prices, SWAV is priced at $334.75, while RCEL trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas RCEL's P/E ratio is -2.70. In terms of profitability, SWAV's ROE is +0.25%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, SWAV is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs LNSR Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, LNSR has a market cap of 166.39M. Regarding current trading prices, SWAV is priced at $334.75, while LNSR trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas LNSR's P/E ratio is -5.17. In terms of profitability, SWAV's ROE is +0.25%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, SWAV is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs TLSI Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, TLSI has a market cap of 166.20M. Regarding current trading prices, SWAV is priced at $334.75, while TLSI trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas TLSI's P/E ratio is -3.92. In terms of profitability, SWAV's ROE is +0.25%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, SWAV is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs CVRX Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, CVRX has a market cap of 165.30M. Regarding current trading prices, SWAV is priced at $334.75, while CVRX trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas CVRX's P/E ratio is -2.96. In terms of profitability, SWAV's ROE is +0.25%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, SWAV is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs MASS Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, MASS has a market cap of 164.24M. Regarding current trading prices, SWAV is priced at $334.75, while MASS trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas MASS's P/E ratio is -2.16. In terms of profitability, SWAV's ROE is +0.25%, compared to MASS's ROE of -0.13%. Regarding short-term risk, SWAV is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs INGN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, INGN has a market cap of 163.74M. Regarding current trading prices, SWAV is priced at $334.75, while INGN trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas INGN's P/E ratio is -5.30. In terms of profitability, SWAV's ROE is +0.25%, compared to INGN's ROE of -0.15%. Regarding short-term risk, SWAV is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs AVR Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, AVR has a market cap of 149.15M. Regarding current trading prices, SWAV is priced at $334.75, while AVR trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas AVR's P/E ratio is -2.10. In terms of profitability, SWAV's ROE is +0.25%, compared to AVR's ROE of -2.92%. Regarding short-term risk, SWAV is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs PROF Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, PROF has a market cap of 141.55M. Regarding current trading prices, SWAV is priced at $334.75, while PROF trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas PROF's P/E ratio is -3.89. In terms of profitability, SWAV's ROE is +0.25%, compared to PROF's ROE of -0.70%. Regarding short-term risk, SWAV is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs RPID Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, RPID has a market cap of 140.70M. Regarding current trading prices, SWAV is priced at $334.75, while RPID trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas RPID's P/E ratio is -3.12. In terms of profitability, SWAV's ROE is +0.25%, compared to RPID's ROE of -0.56%. Regarding short-term risk, SWAV is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs LUNG Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, LUNG has a market cap of 138.08M. Regarding current trading prices, SWAV is priced at $334.75, while LUNG trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas LUNG's P/E ratio is -2.38. In terms of profitability, SWAV's ROE is +0.25%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, SWAV is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs LUCD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, LUCD has a market cap of 136.32M. Regarding current trading prices, SWAV is priced at $334.75, while LUCD trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas LUCD's P/E ratio is -1.20. In terms of profitability, SWAV's ROE is +0.25%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, SWAV is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs MYO Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, MYO has a market cap of 128.08M. Regarding current trading prices, SWAV is priced at $334.75, while MYO trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas MYO's P/E ratio is -25.43. In terms of profitability, SWAV's ROE is +0.25%, compared to MYO's ROE of -0.36%. Regarding short-term risk, SWAV is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ICAD Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ICAD has a market cap of 109.51M. Regarding current trading prices, SWAV is priced at $334.75, while ICAD trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ICAD's P/E ratio is -19.00. In terms of profitability, SWAV's ROE is +0.25%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, SWAV is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs HJLI Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, SWAV is priced at $334.75, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas HJLI's P/E ratio is N/A. In terms of profitability, SWAV's ROE is +0.25%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, SWAV is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs XTNT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, XTNT has a market cap of 95.76M. Regarding current trading prices, SWAV is priced at $334.75, while XTNT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas XTNT's P/E ratio is -5.73. In terms of profitability, SWAV's ROE is +0.25%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, SWAV is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs ASXC Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, SWAV is priced at $334.75, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas ASXC's P/E ratio is -1.12. In terms of profitability, SWAV's ROE is +0.25%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, SWAV is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs MGRM Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, MGRM has a market cap of 92.43M. Regarding current trading prices, SWAV is priced at $334.75, while MGRM trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas MGRM's P/E ratio is -5.08. In terms of profitability, SWAV's ROE is +0.25%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, SWAV is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs OWLT Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, OWLT has a market cap of 87.50M. Regarding current trading prices, SWAV is priced at $334.75, while OWLT trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas OWLT's P/E ratio is -3.29. In terms of profitability, SWAV's ROE is +0.25%, compared to OWLT's ROE of +1.37%. Regarding short-term risk, SWAV is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.
SWAV vs NVCN Comparison
SWAV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWAV stands at 12.57B. In comparison, NVCN has a market cap of 82.86M. Regarding current trading prices, SWAV is priced at $334.75, while NVCN trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWAV currently has a P/E ratio of 78.76, whereas NVCN's P/E ratio is -1.99. In terms of profitability, SWAV's ROE is +0.25%, compared to NVCN's ROE of -1.21%. Regarding short-term risk, SWAV is less volatile compared to NVCN. This indicates potentially lower risk in terms of short-term price fluctuations for SWAV.